Clinical trials: Depressive Psychosis
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder, Affective Psychosis, Bipolar
Management of my Bipolarity Intervention in Bipolar Disorder Patients
The Management of my Bipolarity study aims to develop an educational intervention (MoB EI) on the combined use of technology and face to face education on the empowerment of ill health self-management skills in adults with…
- Conditions
- Bipolar Disorder, Affective Psychosis, Bipolar, Manic-Depressive Psychosis, Depression, Bipolar
- Trial name
- MoB (NCT04643210)
- Testing
- F2F MoB EI, MoB DP
- Where
- Cyprus
- Volunteers
- 80 people
- Sponsor
- Cyprus University of Technology
Psychosis, Substance Use Disorders
Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
The purpose of this trial is to determine if patients with comorbid psychotic disorder and substance use disorder will continue in treatment longer if treated with clozapine than with olanzapine, and will have greater reductions…
- Trial name
- NCT03857581
- Testing
- Clozapine, Olanzapine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Augusta University
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Type 2 Diabetes Mellitus, Schizophrenia
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population.
- Conditions
- Type 2 Diabetes Mellitus, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- Healthy_LIFE (NCT01828931)
- Testing
- Lifestyle Intervention, Usual Care
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Postpartum Depression, Major Depressive Disorder
Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression
The project aimed at identifying neuropsychobiological signatures of pharmacological sex-steroid hormone manipulations in healthy women as a risk model for depression.
- Conditions
- Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis, Menopause
- Trial name
- GnRHa (NCT02661789)
- Testing
- Goserelin 3.6 mg implant
- Where
- Denmark
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gitte Moos Knudsen
Psychosis, Major Depression
Peer Support for Severe Mental Disorders
The purpose of this study is to determine wether peer support is effective for the treatment of people with severe mental illness.
- Conditions
- Psychosis, Major Depression, Bipolar Disorder, Borderline Personality Disorder
- Trial name
- PEER (NCT02276469)
- Testing
- peer support
- Volunteers
- 200 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Psychosis, Schizophrenia
Cognitive Behavioral Therapy for Patients With an Early Psychosis
The purpose of the present study is to examine whether cognitive behavior therapy will reduce depressive symptoms and increase self-esteem for patients with a first episode psychosis.
- Conditions
- Psychosis, Schizophrenia, Depressive Symptoms, Self-esteem
- Trial name
- NCT01511406
- Testing
- cognitive behavioral therapy
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Depression, Bipolar
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.
- Conditions
- Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
- Trial name
- NCT00422214
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 54 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca